TrialPancreas2013

Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.

Christina Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.